SEC Comment Letter 0000000000-25-002909 to Xilio Therapeutics, Inc. (XLO)
Xilio Therapeutics, Inc.
Date: March 17, 2025 · CIK: 0001840233 · Accession: 0000000000-25-002909
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-285703
Letter
Re: Xilio Therapeutics, Inc. Registration Statement on Form S-3 Filed March 11, 2025 File No. 333-285703 Dear Ren Russo:
March 17, 2025
Ren Russo President and Chief Executive Officer Xilio Therapeutics, Inc. 828 Winter Street, Suite 300 Waltham, MA 02451
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Alan Campbell at 202-551-4224 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Molly W. Fox, Esq.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> March 17, 2025 Ren Russo President and Chief Executive Officer Xilio Therapeutics, Inc. 828 Winter Street, Suite 300 Waltham, MA 02451 Re: Xilio Therapeutics, Inc. Registration Statement on Form S-3 Filed March 11, 2025 File No. 333-285703 Dear Ren Russo: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Alan Campbell at 202-551-4224 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Molly W. Fox, Esq. </TEXT> </DOCUMENT>